Potency and stability of C terminal truncated human epidermal growth factor

Gut

Volumn 47, Issue 5, 2000, Pages 622-627

  Calnan, D P ^a   Fagbemi, A ^b   Berlanga Acosta, J ^c   Marchbank, T ^b   Sizer, T ^b   Lakhoo, K ^b   Edwards, A D ^b   Playford, R J ^b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Epidermal growth factor; Intestinal injury; Nutrition

Indexed keywords

RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INTESTINE INJURY; LIVER CELL CULTURE; MALE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SACCHAROMYCES CEREVISIAE;

ANALYSIS OF VARIANCE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; EPIDERMAL GROWTH FACTOR; GASTRIC MUCOSA; HUMANS; MALE; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STOMACH DISEASES; THYMIDINE;

EID: 0033760517     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.5.622     Document Type: Article

References (26)

1. Immunohistochemical localisation of urogastrone to human duodenal and submaxillary glands
2. Human EGF precursor: cDNA sequence, expression in vitro and gene organisation
3. Epidermal growth factor is digested to smaller, less active forms in acid gastric juice
4. Stability of recombinant epidermal growth factor in various solutions
5. Purification and characterization of High Molecular Weight Human Epidermal growth factor from human urine
6. Intravenous epidermal growth factor/urogastrone increases small intestinal cell proliferation in congenital microvillus atrophy
7. Urogastrone/ epidermal growth factor in treatment of congenital microvillus atrophy
8. Epidermal growth factor in necrotising enteritis
9. A pilot study of the safety and efficacy of epidermal growth factor (rEGF) in the treatment of severe necrotising enterocolitis
10. Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer
11. Gastric ulcer treatment with intravenous human epidermal growth factor; A double-blind controlled clinical study
12. The contribution of C-terminal undecapeptide sequence of urogastrone-epidermal growth factor to its biological action
13. Comparison of the mitogenic activity of human EGF1-53 and EGF1-48 in vitro and in vivo
14. Rapid identification of proteins by peptide-mass fingerprinting
15. Hormonal stimulation of DNA synthesis in primary cultures of adult rat hepatocytes
16. Dose dependent effects of fentanyl on indomethacin-induced gastric damage
17. Effect of luminal growth factor preservation on intestinal growth
18. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract
19. Epidermal growth factor-urogastrone: Biological activity and receptor binding of derivatives
20. Review article: Controversies in NSAID-induced gastroduodenal damage - Do they matter?
21. Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion
22. Physiological concentrations of human epidermal growth factor; use of sensitive enzyme immunoassay
23. Mutational analysis of leucine 47 in human epidermal growth factor
24. Rational design for the development of epidermal growth factor receptor antagonists
25. Recombinant peptides for gastrointestinal ulceration: Still early days
26. Effect of epidermal growth factor on experimental colitis in the rat